Research programme: tubulin targeting agents - Veru Healthcare

Drug Profile

Research programme: tubulin targeting agents - Veru Healthcare

Alternative Names: APP 111

Latest Information Update: 19 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ohio State University
  • Developer Veru Healthcare
  • Class Small molecules
  • Mechanism of Action Androgen receptor antagonists; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Prostate cancer

Most Recent Events

  • 30 Sep 2015 Aspen Park Pharmaceuticals acquires the worldwide rights from the Ohio State University, to develop APP 111 and its analogues
  • 30 Sep 2015 Aspen Park Pharmaceuticals has over 21 issued, allowed, and pending patents for APP 111
  • 30 Sep 2015 Preclinical trials in Prostate cancer in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top